Literature DB >> 7530740

Expression and function of the gamma c subunit of the IL-2, IL-4, and IL-7 receptors. Distinct interaction of gamma c in the IL-4 receptor.

Y W He1, B Adkins, R K Furse, T R Malek.   

Abstract

IL-2R, IL-4R, and IL-7R share a common subunit referred to as gamma c and the IL-13R has been proposed to contain gamma c as a subunit. In this report we have used two novel mAbs (3E12 and 4G3) to distinct epitopes of mouse gamma c to determine its lymphoid cell distribution and to examine whether gamma c uses similar epitopes to interact with different cytokines and cytokine receptors. FACS analysis revealed that gamma c is expressed in most lymphocytes, myeloid cells, embryonic thymocytes, and lymphoid cell lines. Results from radiolabeled ligand binding studies, biochemical analysis of ligand-receptor cross-linked complexes, and cytokine bioassays indicate that the epitope defined by mAb 4G3 closely defines the IL-7 binding region of gamma c and overlaps the IL-2 binding region of gamma c. These studies also indicate that gamma c interacts with IL-4 in the context of the IL-4R in a manner that is distinct from its role in the IL-2R and IL-7R and suggest that the 3E12 epitope defines a region of gamma c that intimately interacts with the IL-4R. The B9 plasmacytoma, which proliferates in response to IL-4 and IL-13, was shown to not express gamma c. Thus, at least in some circumstances, gamma c is dispensable for signaling via the IL-4R and is not a required subunit of the IL-13R.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530740

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Gamma chain receptor interleukins: evidence for positive selection driving the evolution of cell-to-cell communicators in the mammalian immune system.

Authors:  Mary J O'Connell; James O McInerney
Journal:  J Mol Evol       Date:  2005-10-04       Impact factor: 2.395

2.  Functional cleavage of the common cytokine receptor gamma chain (gammac) by calpain.

Authors:  M Noguchi; A Sarin; M J Aman; H Nakajima; E W Shores; P A Henkart; W J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain.

Authors:  R L Palmer-Crocker; C C Hughes; J S Pober
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 4.  A primer on cytokines: sources, receptors, effects, and inducers.

Authors:  J H Curfs; J F Meis; J A Hoogkamp-Korstanje
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

5.  Functional interleukin-4 receptor and interleukin-2 receptor common gamma chain in human gastric carcinoma: a possible mechanism for cytokine-based therapy.

Authors:  R Essner; Y Huynh; T Nguyen; M Rose; M Kojima; D S Hoon
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

6.  Blockade of T- and B-lymphocyte development by antibody to the gamma c subunit of the receptors for interleukins 2, 4, and 7.

Authors:  Y W He; R B Levy; T R Malek
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

7.  Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor.

Authors:  D J Hilton; J G Zhang; D Metcalf; W S Alexander; N A Nicola; T A Willson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

8.  Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation.

Authors:  A D Keegan; J A Johnston; P J Tortolani; L J McReynolds; C Kinzer; J J O'Shea; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation.

Authors:  Yoh-Ichi Seki; Katsuhiko Hayashi; Akira Matsumoto; Noriyasu Seki; Jun Tsukada; John Ransom; Tetsuji Naka; Tadamitsu Kishimoto; Akihiko Yoshimura; Masato Kubo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-19       Impact factor: 11.205

10.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.